Ibsrela Now Available for Irritable Bowel Syndrome With Constipation
The approval was based on two phase 3 trials which evaluated Ibsrela in over 1200 adults with IBS-C.
Miscellaneous Gastrohepatic Disorders
Orally Active Amino Acid Mixture Fast Tracked for NASH With Liver Fibrosis
The Company is currently investigating AXA1125 in patients with noncirrhotic NASH with fibrosis in the phase 2b EMMPACT trial.
ACG Issues Guidelines for Managing Acute-on-Chronic Liver Failure
Preferred approach described for managing ACLF, now emerging as a major cause of mortality in patients with cirrhosis, chronic liver disease
Two Doses of BNT162b2 Vaccine Protect Against MIS-C
Two doses of Pfizer-BioNTech vaccine have estimated effectiveness of 91 percent against MIS-C in children aged 12 to 18 years
Factors ID’d for Severe GI Effects of SARS-CoV-2 in Children
Among children infected with SARS-CoV-2, 9.5 percent have severe GI effects, such as disseminated adenomesenteritis, appendicitis, pancreatitis
Benralizumab Gets Orphan Drug, Fast Track Designations for 2 Rare GI Diseases
These rare, chronic relapsing conditions are primarily associated with eosinophilic tissue inflammation.
Oral Prodrug of Testosterone Fast Tracked for Nonalcoholic Steatohepatitis
LPCN 1144 treatment was associated with a statistically significant reduction in liver fat compared with placebo.
Lanifibranor Reduces Disease Activity in Nonalcoholic Steatohepatitis
In phase 2b trial, more patients with active NASH had reduction in disease activity score with lanifibranor versus placebo
ACG Updates Clinical Guidelines for Benign Anorectal Disorders
Anorectal biofeedback therapy recommended in defecation disorders; biofeedback also recommended in proctalgia syndrome
Efruxifermin Fast Tracked for Nonalcoholic Steatohepatitis
Efruxifermin is a differentiated Fc-FGF21 fusion protein designed to mimic the biological activity of fibroblast growth factor 21.
